Bruna Letícia da Silva Santos Geraldo

Bruna Letícia da Silva Santos Geraldo

Auto-generated profile, based on publicly available information

Bruna Letícia da Silva Santos Geraldo

Associação da Medula Óssea - AMEO

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2024 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
ASAnderson João Simione
Anderson João Simione
CSCinthya Corrêa da Silva
Cinthya Corrêa da Silva
PSPaula Moreira da Silva Sabaini
Paula Moreira da Silva Sabaini
AMAntonio Vaz Macedo
Antonio Vaz Macedo
HNHeliz Regina Alves das Neves
Heliz Regina Alves das Neves
FDFernando Barroso Duarte
Fernando Barroso Duarte
The development of the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) allowed for an assessment of the activity and general outcomes of transplants in Brazil. Here, we report an updated activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. Information returns to Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2023 from Brazilian centers were extracted from CIBMTR. Descriptive analysis was carried out by patient-, disease- and transplant-specific variables and overall survival analysis using Kaplan Meyer. A total of 12,230 patients were eligible for this study (5,573 autologous and 6,657 allogeneic transplants). The number of reporting centers increased from 40 to 44 during the period. The most common HCT indication in Brazil is AML for allogeneic HCT with 152 transplants year and multiple myeloma for autologous HCT with 245 transplants per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic transplants, BM was the most frequent among pediatric transplants, while PBSC was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of transplants. Patients with acute leukemia who underwent HCT with advanced stage disease had lower survival rates compared to those at other stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides.

31 May 2023 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
ASAnderson João Simione
Anderson João Simione
HNHeliz Regina Alves Das Neves
Heliz Regina Alves Das Neves
CSCinthya Corrêa Da Silva
Cinthya Corrêa Da Silva
PSPaula Moreira da Silva Sabaini
Paula Moreira da Silva Sabaini
BGBruna Letícia da Silva Santos Geraldo
Bruna Letícia da Silva Santos Geraldo
FDFernando Barroso Duarte
Fernando Barroso Duarte
The first hematopoietic stem cell transplantation (HSCT) program in Latin America started in 1979 at the federal university hospital in Curitiba, Paraná, Brazil. Over the years, the number of centers performing transplants in our country has increased tremendously, generating the need to know the results of this treatment modality. Understanding the HSCT scenario in Brazil is still challenging, since not all Brazilian centers report data to the Center for International Blood and Marrow Research (CIBMTR). Despite the improvement in the number of reporting centers over the past few years, infrastructure and trained data managers are still lacking. The partnership between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the CIBMTR enabled the establishment of the Hematopoietic Stem Cell Transplantation Brazilian Registry (HSCTBR), using the CIBMTR Data Back to Center (DBtC) tool to retrieve Brazilian HSCT data in a standardized and organized way. Since then, it has been possible to gather country-level data on HSCT demographics and transplant outcomes. Between 2012 and 2022, complete information on 9,868 transplants were reported to the CIBMTR from 40 Brazilian transplant centers. The consolidation of the HSCTBR using CIBMTR infrastructure allowed the development and regular update of the Brazilian Summary Slides. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides. In this paper we present the 2023 SBTMO-CIBMTR Summary Slides prepared by the SBTMO data managers (GD-SBTMO).

1 March 2020 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RSRoberto Luiz da Silva
Roberto Luiz da Silva
LSLucas Augusto Monetta da Silva
Lucas Augusto Monetta da Silva
BGBruna Leticia da Silva Santos Geraldo
Bruna Leticia da Silva Santos Geraldo
ASAline de Almeida Simões
Aline de Almeida Simões
MAManuella de Souza Sampaio Almeida
Manuella de Souza Sampaio Almeida
MMMaria Cristina Martins de Almeida Macedo
Maria Cristina Martins de Almeida Macedo
Hematopoietic stem cell transplantation (HSCT) has been used to treat many malignant and nonmalignant hematologic conditions; however, the use of HSCT in patients who refuse blood transfusions has rarely been described in the literature, and no data have been published concerning haploidentical HSCT without the use of blood products. The aim of this study is to describe the experience of a Brazilian group in performing 21 HSCTs without the use of blood components in the first 100 days after transplantation, which is the period corresponding to the greatest risk of toxicity for this procedure. We developed 21 HSCTs without transfusion support in 19 patients admitted to 2 Brazilian transplantation centers. The patients were subjected to stem cell mobilization and different conditioning regimens. No mortality related to the procedure occurred among the transplant recipients. The global survival rate after 100 days, which is the period related to the immediate toxicity of HSCT, was 94.7%, and the median duration of follow-up was 980 days, with an overall survival rate of 68.4%. Thus, refusal of blood transfusion is not an absolute contraindication for HSCT. This therapy is feasible in specific situations when the patient clearly expresses a desire to avoid blood transfusions and when favorable clinical conditions are achievable with strict, specialized medical monitoring.

1 March 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AVAfonso Celso Vigorito
Afonso Celso Vigorito
EMEliana C M Miranda
Eliana C M Miranda
VCVergilio A.R. Colturato
Vergilio A.R. Colturato
ASAnderson João Simioni
Anderson João Simioni
VFVaneuza ARAUJO MOREIRA Funke
Vaneuza ARAUJO MOREIRA Funke
MFMary E.D. Flowers
Mary E.D. Flowers

8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
CSCinthya Corrêa da Silva
Cinthya Corrêa da Silva
HNHeliz Regina Alves das Neves
Heliz Regina Alves das Neves
ASAnderson João Simione
Anderson João Simione
AYAlayne Magalhães Trindade Domingues Yamada
Alayne Magalhães Trindade Domingues Yamada
AMAntonio Vaz de Macedo
Antonio Vaz de Macedo
MPMarcelo C. Pasquini
Marcelo C. Pasquini
Hematopoietic cell transplantation is a data-driven field, and reporting to outcomes registries has become a common practice worldwide. However, comprehensive transplant data collection requires dedicated professionals who can accurately capture data, follow international guidelines, and maintain reliable databases for the evaluation of transplant outcomes. This article describes the development and evolution of the Brazilian Data Managers Working Group (GTGD) and its contributions to professional education, collaborative networking, registry implementation, data quality improvement, and scientific engagement in hematopoietic cell transplantation and cellular therapy in Brazil. The transition from single-center reporting to the establishment of a national transplant registry required collaboration among centers, partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and the development of the GTGD to ensure the sustainability of this effort. The GTGD originated from a grassroots collaboration among data managers and transplant centers seeking to address limited professional recognition, inconsistent reporting practices, and restricted access to specialized training. Supported by collaboration with the SBTMO and CIBMTR, the initiative evolved into a nationally coordinated network. Over the decade, the GTGD promoted structured education, knowledge sharing, professional development, operational support, standardized data-management practices, quality-improvement initiatives, and scientific collaboration. In parallel, participation in the national multicenter protocol expanded to 95 centers, with 51 centers reporting data to the CIBMTR by 2025. The group also developed educational resources, supported benchmarking and cellular therapy reporting, strengthened national and international collaboration, and increased the visibility and professional identity of data managers within transplant programs. This experience demonstrates how coordinated engagement, continuous education, institutional collaboration, and professional advocacy can contribute to the development of national registry infrastructure and the generation of reliable real-world evidence in hematopoietic cell transplantation and cellular therapy.

12 May 2024 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
HNHeliz Regina Alves das Neves
Heliz Regina Alves das Neves
ASAnderson João Simione
Anderson João Simione
CSCinthya Corrêa da Silva
Cinthya Corrêa da Silva
PSPaula Moreira da Silva Sabaini
Paula Moreira da Silva Sabaini
BGBruna Letícia Da Silva Santos Geraldo
Bruna Letícia Da Silva Santos Geraldo
FDFernando Barroso Duarte
Fernando Barroso Duarte
Since the first hematopoietic stem cell transplantation (HSCT) was performed at the Federal University Hospital (Curitiba, PR) in 1979, the number of centers offering this modality of treatment has increased. However, accessing comprehensive HSCT outcomes has become a challenge due to lack of an official Brazilian registry. The partnership between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the Center for International Blood and Marrow Research (CIBMTR) was an important milestone in the establishment of the HSCT Brazilian registry (HSCTBR). By using CIBMTR’s Data Back to Center (DBtC) tool, we have gained insights into HSCT outcomes through the Brazilian Summary Slides. While understanding the country's transplant scenario is crucial, it is equally important for each center to assess their own outcomes. In order to help the Brazilian centers with the CIBMTR, the data manager of SBTMO working group has developed a business tool solution to facilitate this important task.